Bifogade filer
PDF
Kurs
-0,41%
Likviditet
453 MSEK
Kalender
| Est. tid* | ||
| 2026-10-27 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-16 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-06 | N/A | Årsstämma |
| 2026-04-28 | 08:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-05 | 08:00 | Bokslutskommuniké 2025 |
| 2025-10-23 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-16 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-09 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2025-05-08 | - | Årsstämma |
| 2025-04-29 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-05 | - | Bokslutskommuniké 2024 |
| 2024-12-11 | - | Extra Bolagsstämma 2025 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-10-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-15 | - | Extra Bolagsstämma 2023 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2023-05-09 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-08 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-21 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2021-05-04 | - | Årsstämma |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2020-05-13 | - | Årsstämma |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-17 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-10 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-10-31 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-18 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-11 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2018-05-09 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-10-25 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-19 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-05 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2017-05-04 | - | Årsstämma |
| 2017-04-28 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-24 | - | Årsstämma |
| 2016-05-20 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2016-04-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-17 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2015-05-06 | - | Årsstämma |
| 2015-05-06 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | - | Bokslutskommuniké 2014 |
| 2014-10-30 | - | Analytiker möte 2014 |
| 2014-10-30 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-18 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-09 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2014-05-08 | - | Årsstämma |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-20 | - | Bokslutskommuniké 2013 |
| 2013-11-05 | - | Kapitalmarknadsdag 2013 |
| 2013-11-05 | - | Analytiker möte 2013 |
| 2013-10-30 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-18 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2013-04-26 | - | Årsstämma |
| 2013-04-26 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-21 | - | Bokslutskommuniké 2012 |
| 2012-10-30 | - | Analytiker möte 2012 |
| 2012-10-30 | - | Kvartalsrapport 2012-Q3 |
| 2012-07-19 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2012-04-26 | - | Årsstämma |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-23 | - | Bokslutskommuniké 2011 |
| 2011-11-29 | - | Kapitalmarknadsdag 2011 |
| 2011-10-20 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-24 | - | Extra Bolagsstämma 2011 |
| 2011-07-19 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2011-04-28 | - | Årsstämma |
| 2011-04-20 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-23 | - | Bokslutskommuniké 2010 |
| 2010-10-26 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-20 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-28 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2010-04-27 | - | Kvartalsrapport 2010-Q1 |
| 2009-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2008-04-25 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
| 2007-05-04 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately SEK 28.2 B, representing approximately 15 per cent growth at constant exchange rate (CER)[1]. Adjusted EBITA margin1,[2] was approximately 40 per cent of revenues.
- The main reason for the increased revenue was higher than expected Q4 sales for Doptelet, Gamifant and the Haemophilia portfolio.
- The adjusted EBITA margin¹,² was increased due to the higher than expected revenue.
At the publication of the Q3 2025 report on 20 October 2025 Sobi stated the outlook for the full year 2025 to be: Revenue was anticipated to grow by a low double-digit percentage at CER¹ and adjusted EBITA margin¹,² was anticipated to be in the mid to high-30s per cent of revenue.
Sobi will announce its fourth quarter and full year 2025 report on Thursday 5 February 2026 at 8:00 am CET.
Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 12:30 CET on 15 January 2026.
Gerard Tobin
Head of Investor Relations
[1] Alternative Performance Measures (APMs).
[2] Excluding items affecting comparability (IAC).